Clinical Trial Update: A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

View source ↗

Summary

This completed prospective observational study evaluated quality of life and costs in real-world patients treated with 90Y-Zevalin (ibritumomab tiuxetan) for fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: Bayer | Conditions: Lymphoma, Follicular, Non-Hodgkin Lymphoma | Status: COMPLETED